TPCN2 and neurodevelopmental disorder: Finally, targeting TPC2 with agonists may offer a new therapeutic approach to potentiate the physiologically timed endogenous local release of OT in neurodevelopmental disorders characterized by social interaction deficits, thus bypassing current problems such as receptor desensitization with exogenous OT replacement therapies (92).